Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock … Continue reading NASDAQ Gainers: Ariad Pharmaceuticals (NASDAQ:ARIA), Yandex NV (NASDAQ:YNDX), GT Advanced Technologies (NASDAQ:GTAT), Oculus Innovative Sciences (NASDAQ:OCLS)